共 418 条
[1]
Steigbigel RT(2008)Raltegravir with optimized background therapy for resistant HIV-1 infection N Engl J Med 359 339-354
[2]
Cooper DA(2009)The use of integrase inhibitors in treatment-experienced patients Eur J Med Res 14 30-35
[3]
Kumar PN(2011)Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium Ann N Y Acad Sci 1222 83-89
[4]
Eron JE(2011)Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies AIDS 25 1365-1369
[5]
Schechter M(2009)Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Lancet 374 796-806
[6]
Markowitz M(2010)Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses J Acquir Immune Defic Syndr 55 39-48
[7]
Loutfy MR(2008)Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection Pharmacotherapy 28 90-101
[8]
Lennox JL(2008)Integrase inhibitors: a clinical review of raltegravir and elvitegravir J HIV Ther 13 36-39
[9]
Gatell JM(2008)New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists J Infect 57 1-10
[10]
Rockstroh JK(2012)Dolutegravir–a promising antiretroviral in development Lancet Infect Dis 12 90-91